This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study
to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of
JCAR017 in combination with various agents. This protocol is intended to evaluate various
drug combinations with JCAR017, as separate arms, over the life of...Read More
the protocol, using the
same objectives. Each combination will be evaluated separately (ie, the intention is not to
compare between combinations) for the purposes of the objectives, trial design, and
statistical analysis. The following combinations will be tested:
Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122
(avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in
combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm
F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment
once combination agents have been selected.
The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose
expansion may occur in one or more arms.Read Less
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.
